Proposed Data Collection Submitted for Public Comment and Recommendations, 53376-53377 [2020-18997]
Download as PDF
<![CDATA[
53376
Federal Register / Vol. 85, No. 168 / Friday, August 28, 2020 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
responses per
respondent
Number of
respondents
Average
burden per
response
(in minutes)
Total burden
hours
Respondent
Form
Cruise ship operator .........................
Attestation statement of COVID–19
free ship (for repatriating crew via
commercial travel).
100
1
20/60
33
Total ...........................................
...........................................................
........................
........................
........................
4,134
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–19010 Filed 8–27–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Please note: Submit all comments through
the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
Centers for Disease Control and
Prevention
[60Day–20–1218; Docket No. CDC–2020–
0091]
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled ‘‘Evaluation of MedicationAssisted Treatment (MAT) for Opioid
use disorder.’’ CDC will use the
collection to continue the epidemiologic
study to assess the type of MAT
(methadone maintenance;
buprenorphine; naltrexone; or,
counseling, no MAT), and the
contextual, provider, and individual
factors that influence implementation
and improved patient wellbeing.
DATES: Written comments must be
received on or before October 27, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0091 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
VerDate Sep<11>2014
17:16 Aug 27, 2020
Jkt 250001
To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
FOR FURTHER INFORMATION CONTACT:
Proposed Data Collection Submitted
for Public Comment and
Recommendations
SUMMARY:
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.
Proposed Project
Evaluation of Medication-Assisted
Treatment (MAT) for Opioid Use
Disorder—Revision—National Center
for Injury Prevention and Control
(NCIPC), Centers for Disease Control
and Prevention (CDC)
Background and Brief Description
CDC seeks a one-year OMB approval
to continue collecting data for
Medication-Assisted Treatment (MAT)
for Opioid use disorder. Approximately
2.4 million people aged 18 or older have
opioid use disorders (OUDs) in the
United States. At any given time, only
half of these people receive some form
of treatment, which may include
medication-assisted treatment (MAT) or
abstinence-based psychotherapy or selfhelp treatments (i.e., counseling without
medication [COUN]). The rise in opioid
overdose deaths, up from 2014–2015
due partly to a 72% rise in synthetic
opioid overdose deaths alone, shows
that engaging and retaining clients in
OUD treatment is an urgent public
health need. Only a few studies are
available to help clients and providers
make informed decisions about the risks
and benefits associated with the
different types of MATs. This
information is crucial because even
though each MAT drug helps prevent
withdrawal symptoms and decreases
cravings, differences in treatment
approach and settings influence how
people respond to the medication and,
thus, their long-term treatment success.
E:\FR\FM\28AUN1.SGM
28AUN1
53377
Federal Register / Vol. 85, No. 168 / Friday, August 28, 2020 / Notices
The purpose of this study is to
conduct an epidemiologic, mixedmethods evaluation of OUD treatment in
real-world outpatient settings. Client
recruitment for this study was originally
scheduled to take place between 5/1/
2018 and 8/31/2019, however patient
recruitment levels were lower than
originally anticipated. The recruitment
period was extended to 11/30/2019 to
enable to recruit additional patients.
Because the follow-up period for this
such as multilevel latent growth models,
propensity score matching, latent class
analysis and advance mediation
analysis and qualitative methods such
as interactive coding and analysis for
common themes. There are no costs to
respondents other than their time. The
only cost to respondents will be time
spent responding to the survey/screener.
CDC requests approval for 300
annualized burden hours.
study is 18 months, patients recruited
during the extended recruitment period
(8/31/2019 to 11/30/2019) will need to
complete their final 18-Month Patient
Questionnaire between 2/28/2021 and
5/31/2021, which is after the current
OMB expiration date. The extended
time period is only needed for one of
the data collection instruments, thus
there is a reduction in burden of 3839
hours.
The study uses a mixed-method
approach using quantitative methods
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total
burden
hours
Type of respondent
Form name
Patients .............................................
Client Questionnaire 18-Month Follow-up.
400
1
45/60
300
Total ...........................................
...........................................................
........................
........................
........................
300
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–18997 Filed 8–27–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–20–20QN; Docket No. CDC–2020–
0085]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on ‘‘Availability, Use, and
Public Health Impact of Emergency
Supply Kits among Disaster-Affected
Populations.’’ The goal of this study is
to determine the efficacy and public
health impact of emergency supply kits
among disaster-affected populations to
SUMMARY:
VerDate Sep<11>2014
17:16 Aug 27, 2020
Jkt 250001
understand how emergency supply kits
are used during and after a natural
disaster, if public health outcomes are
associated with access to emergency
supply kits, and what the most useful
items to include in an emergency
supply kit are across different types of
disasters.
DATES: Written comments must be
received on or before October 27, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0085 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to Regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
Regulations.gov.
Please note: All public comment
should be submitted through the
Federal eRulemaking portal
(Regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffry Zirger,
Information Collection Review Office,
Centers for Disease Control and
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 85, Number 168 (Friday, August 28, 2020)]
[Notices]
[Pages 53376-53377]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-18997]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-20-1218; Docket No. CDC-2020-0091]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on a proposed
information collection project titled ``Evaluation of Medication-
Assisted Treatment (MAT) for Opioid use disorder.'' CDC will use the
collection to continue the epidemiologic study to assess the type of
MAT (methadone maintenance; buprenorphine; naltrexone; or, counseling,
no MAT), and the contextual, provider, and individual factors that
influence implementation and improved patient wellbeing.
DATES: Written comments must be received on or before October 27, 2020.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2020-
0091 by any of the following methods:
Federal eRulemaking Portal: Regulations.gov. Follow the
instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to Regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (regulations.gov) or by U.S. mail to the address listed
above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email:
[email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected; and
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses.
5. Assess information collection costs.
Proposed Project
Evaluation of Medication-Assisted Treatment (MAT) for Opioid Use
Disorder--Revision--National Center for Injury Prevention and Control
(NCIPC), Centers for Disease Control and Prevention (CDC)
Background and Brief Description
CDC seeks a one-year OMB approval to continue collecting data for
Medication-Assisted Treatment (MAT) for Opioid use disorder.
Approximately 2.4 million people aged 18 or older have opioid use
disorders (OUDs) in the United States. At any given time, only half of
these people receive some form of treatment, which may include
medication-assisted treatment (MAT) or abstinence-based psychotherapy
or self-help treatments (i.e., counseling without medication [COUN]).
The rise in opioid overdose deaths, up from 2014-2015 due partly to a
72% rise in synthetic opioid overdose deaths alone, shows that engaging
and retaining clients in OUD treatment is an urgent public health need.
Only a few studies are available to help clients and providers make
informed decisions about the risks and benefits associated with the
different types of MATs. This information is crucial because even
though each MAT drug helps prevent withdrawal symptoms and decreases
cravings, differences in treatment approach and settings influence how
people respond to the medication and, thus, their long-term treatment
success.
[[Page 53377]]
The purpose of this study is to conduct an epidemiologic, mixed-
methods evaluation of OUD treatment in real-world outpatient settings.
Client recruitment for this study was originally scheduled to take
place between 5/1/2018 and 8/31/2019, however patient recruitment
levels were lower than originally anticipated. The recruitment period
was extended to 11/30/2019 to enable to recruit additional patients.
Because the follow-up period for this study is 18 months, patients
recruited during the extended recruitment period (8/31/2019 to 11/30/
2019) will need to complete their final 18-Month Patient Questionnaire
between 2/28/2021 and 5/31/2021, which is after the current OMB
expiration date. The extended time period is only needed for one of the
data collection instruments, thus there is a reduction in burden of
3839 hours.
The study uses a mixed-method approach using quantitative methods
such as multilevel latent growth models, propensity score matching,
latent class analysis and advance mediation analysis and qualitative
methods such as interactive coding and analysis for common themes.
There are no costs to respondents other than their time. The only cost
to respondents will be time spent responding to the survey/screener.
CDC requests approval for 300 annualized burden hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Type of respondent Form name respondents responses per response (in hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Patients...................... Client 400 1 45/60 300
Questionnaire
18-Month Follow-
up.
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 300
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2020-18997 Filed 8-27-20; 8:45 am]
BILLING CODE 4163-18-P
